Efbemalenograstim alfa (F 627) is a recombinant fusion protein. Efbemalenograstim alfa is a long acting dimeric granulocyte colony-stimulating factor (G-CSF) that contains two human G-CSF fused to a human immunoglobulin G2 (hIgG2)-Fc fragment with a peptide linker. Efbemalenograstim alfa induces the production of white blood cells.
References:
[1]. Daley W, et, al. Evive successfully concludes first phase III clinical trial of F-627 for chemotherapy-induced neutropenia and met primary endpoints. Shanghai, China: Evive Biotech; January 25, 2018.